AbCellera Biologics (ABCL) AI Stock Analysis

• Market Cap: $1.12B
• Dividend Yield: N/A
• Average Volume (3M): 4.66M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.48
• Revenue Growth: 7.16%
• EPS Growth: 3.95%
• Country: US
• Employees: 596
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.19
• Shares Outstanding: 299,335,050
• 10 Day Avg. Volume: 4,164,915
• 30 Day Avg. Volume: 4,658,006
• PEG Ratio: -0.68
• Price to Book (P/B): 0.82
• Price to Sales (P/S): 29.91
• P/FCF Ratio: -4.61
• Enterprise Value/Market Cap: 1.01
• Enterprise Value/Revenue: 31.84
• Enterprise Value/Gross Profit: 39.80
• Enterprise Value/Ebitda: -6.04
• 1Y Price Target: $6.67
• Price Target Upside: 92.22% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): -0.64
• Revenue Forecast (FY): $35.63M

• Rating: 44 Neutral
• Price Target: $4.00 ▲(15.27% Upside)

AbCellera Biologics' overall stock score is primarily impacted by its financial performance and technical analysis. The company's significant financial challenges, including declining revenues and profitability issues, weigh heavily on the score. Technical indicators suggest bearish momentum, further contributing to a lower score. While the earnings call provides some optimism with a strategic shift towards clinical-stage biotech and strong liquidity, the immediate financial pressures and valuation concerns remain significant.

Positive Factors

Transition to Clinical-Stage Biotech

Transitioning to a clinical-stage biotech allows AbCellera to capture more value from its innovations, potentially leading to higher long-term revenue and strategic growth opportunities.

Strong Liquidity Position

A strong liquidity position provides financial flexibility to invest in R&D and strategic initiatives, supporting long-term growth and stability.

New Clinical Manufacturing Facility

The new facility enhances AbCellera's capacity to develop and manufacture clinical-grade products, supporting its transition to a clinical-stage company and long-term operational efficiency.

Negative Factors

Increased Net Loss

Rising net losses can strain financial resources, potentially limiting investment in growth initiatives and affecting long-term profitability.

Rise in Research and Development Expenses

While increased R&D spending can drive innovation, it also pressures margins and requires careful management to ensure sustainable financial health.

Stagnation in Partner-Initiated Programs

Stagnation in partner-initiated programs may indicate challenges in advancing collaborations, potentially impacting future revenue streams and growth prospects.

AbCellera Biologics Business Overview & Revenue Model

Company Description

AbCellera Biologics (ABCL) is a biotechnology company based in Canada, specializing in the discovery and development of monoclonal antibodies. The company leverages its innovative technology platform, which combines high-throughput screening and machine learning, to identify and optimize antibodies for various therapeutic applications. AbCellera collaborates with pharmaceutical and biotechnology companies to accelerate the development of antibody-based therapies, contributing to advancements in the treatment of diseases such as cancer and autoimmune disorders.

How the Company Makes Money

AbCellera generates revenue primarily through its partnerships and collaborations with pharmaceutical companies, where it provides its antibody discovery services. The company typically enters into agreements that include upfront payments, research funding, and milestone payments based on the progress of drug development. Additionally, AbCellera may receive royalties on sales of products that result from these collaborations. The company's revenue model is heavily reliant on the successful advancement of its partners' therapeutic candidates, along with ongoing research contracts and collaborations that can provide continuous income streams.

AbCellera Biologics Financial Statement Overview

Summary

AbCellera Biologics faces significant financial challenges, with declining revenues and profitability issues impacting its income statement. The balance sheet remains strong with low leverage, but cash flow struggles highlight operational inefficiencies. The company needs to focus on improving revenue stability and profitability to enhance its financial health.

Income Statement

AbCellera Biologics has experienced significant revenue volatility, with a notable decline in revenue from 2022 to 2025. The company is currently operating at a loss, with negative net profit and EBIT margins, indicating profitability challenges. However, there was a slight revenue growth in the TTM period, suggesting potential recovery.

Balance Sheet

The balance sheet shows a relatively low debt-to-equity ratio, indicating conservative leverage. However, the negative return on equity in recent periods highlights profitability issues. The equity ratio remains stable, suggesting a strong capital structure despite operational losses.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows, reflecting cash management challenges. Despite this, the free cash flow to net income ratio is positive, indicating some efficiency in converting earnings to cash. The recent growth in free cash flow is a positive sign, but overall cash flow health remains weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	35.32M	28.83M	38.02M	485.42M	375.20M	233.16M
Gross Profit	28.27M	28.83M	38.02M	418.99M	329.69M	206.01M
EBITDA	-186.27M	-204.15M	-192.16M	260.17M	239.15M	169.62M
Net Income	-171.68M	-162.86M	-146.40M	158.52M	153.46M	118.92M
Balance Sheet
Total Assets	1.36B	1.36B	1.49B	1.54B	1.32B	1.01B
Cash, Cash Equivalents and Short-Term Investments	520.67M	625.61M	760.59M	886.49M	722.98M	594.12M
Total Debt	137.05M	65.36M	77.38M	82.26M	40.06M	6.78M
Total Liabilities	391.95M	304.47M	335.78M	307.63M	292.84M	175.03M
Stockholders Equity	964.04M	1.06B	1.15B	1.23B	1.03B	830.51M
Cash Flow
Free Cash Flow	-153.11M	-186.95M	-121.38M	204.70M	186.13M	8.02M
Operating Cash Flow	-104.55M	-108.56M	-43.88M	277.36M	244.58M	22.69M
Investing Cash Flow	48.31M	121.41M	-221.11M	-352.63M	-332.25M	-119.78M
Financing Cash Flow	14.11M	12.77M	10.36M	-1.63M	-3.89M	683.65M

AbCellera Biologics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.47
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABCL, the sentiment is Negative. The current price of 3.47 is below the 20-day moving average (MA) of 3.93, below the 50-day MA of 4.89, and below the 200-day MA of 3.64, indicating a bearish trend. The MACD of -0.41 indicates Negative momentum. The RSI at 32.18 is Neutral, neither overbought nor oversold. The STOCH value of 56.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ABCL.

AbCellera Biologics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RCUS	57 Neutral	$3.23B	―	-68.13%	―	-8.75%	-8.79%
DNTH	55 Neutral	$1.32B	-10.20	-28.57%	―	-42.64%	-39.78%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SNDX	48 Neutral	$1.72B	―	-129.32%	―	597.19%	0.45%
ABCL	44 Neutral	$1.12B	―	-16.81%	―	7.16%	3.95%
EWTX	40 Underperform	$2.68B	―	-30.02%	―	―	-5.73%
GPCR	31 Underperform	$2.17B	―	-25.31%	―	―	-64.91%

AbCellera Biologics Corporate Events

AbCellera Appoints Dr. Stephen Quake to Board

On November 10, 2025, AbCellera Biologics announced the appointment of Dr. Stephen Quake to its Board of Directors, enhancing the company’s commitment to scientific excellence. Dr. Quake, a renowned scientist and entrepreneur, brings extensive expertise in fields such as genomics and molecular diagnostics, aligning with AbCellera’s strategic goals. Concurrently, Andrew Lo resigned from the board, having contributed significantly to the company’s business and strategy since 2021.

The most recent analyst rating on (ABCL) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on AbCellera Biologics stock, see the ABCL Stock Forecast page.

AbCellera Biologics’ Earnings Call: Key Insights

AbCellera Biologics, Inc. recently held its earnings call, revealing a mix of optimism and challenges. The company successfully transitioned to a clinical-stage biotech, showcasing its strong liquidity position. However, increased net loss and R&D expenses were noted, alongside a stagnation in partner-initiated programs, presenting a nuanced sentiment in the earnings call.

AbCellera Biologics Reports Q3 2025 Financial Results

AbCellera Biologics Inc. is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based medicines across various therapeutic areas, including endocrinology, women’s health, immunology, and oncology.

AbCellera Biologics Reports Q3 2025 Financial Results

AbCellera Biologics reported its financial results for the third quarter of 2025, highlighting the start of activities at its new clinical manufacturing facility and substantial completion of platform investments. The company ended the quarter with $680 million in available liquidity, despite a net loss of $57.1 million. Key developments included the appointment of a new Chief Medical Officer and progress in Phase 1 clinical trials for its lead programs. The company also reported an increase in partner-initiated program starts and molecules advanced into the clinic, reflecting its strategic focus on expanding its pipeline.

The most recent analyst rating on (ABCL) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on AbCellera Biologics stock, see the ABCL Stock Forecast page.

AbCellera’s ABCL635 Study: A Promising Step for Menopause Treatment

AbCellera Biologics Inc. is conducting a Phase 1 clinical study titled ‘A First-in-Human Phase 1 Study of ABCL635 in Healthy Participants and in Postmenopausal Women With Moderate-to-Severe Vasomotor Symptoms’. The study aims to evaluate the effects of ABCL635, a biological intervention, on vasomotor symptoms (VMS) associated with menopause, focusing on safety, tolerability, and pharmacokinetic and pharmacodynamic parameters.

AbCellera’s Phase 1 Study of ABCL575: A Potential Game-Changer?

AbCellera Biologics Inc. is conducting a first-in-human Phase 1 study titled ‘A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy Participants.’ The study aims to evaluate the safety and tolerability of ABCL575, a new biological treatment, in healthy individuals through a single ascending dose approach compared to a placebo. This research is significant as it marks the initial step in assessing ABCL575’s potential therapeutic benefits.

AbCellera Biologics Appoints New Chief Medical Officer

On September 10, 2025, AbCellera Biologics announced the appointment of Dr. Sarah Noonberg as its Chief Medical Officer. Dr. Noonberg brings over two decades of experience in clinical development and will play a crucial role in advancing AbCellera’s pipeline of antibody-based therapeutics as the company transitions to a clinical-stage entity. Her previous roles include Chief Medical Officer at Metagenomi and contributions to the development of enzalutamide for prostate cancer at Medivation.

The most recent analyst rating on (ABCL) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on AbCellera Biologics stock, see the ABCL Stock Forecast page.

AbCellera Biologics Earnings Call: Clinical Progress and Financial Insights

AbCellera Biologics, Inc. recently held its earnings call, revealing a mix of optimism and caution. The company showcased significant advancements in clinical trials and a robust financial standing, marked by increased revenue and pipeline development. However, the call also acknowledged a net loss and an expected decline in research fee revenue, painting a complex picture of the company’s current state.